Enterprise Value
-66.81M
Cash
112.4M
Avg Qtr Burn
-2.25K
Short % of Float
0.47%
Insider Ownership
28.58%
Institutional Own.
42.27%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LAVA-1207 Details Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer, Prostate disease | Phase 1/2 Data readout | |
LAVA-051 ( gamma-delta bsTCE targeting CD1d-expressing tumors) Details Solid tumor/s, Cancer, Chronic lymphocytic leukemia, Acute myeloid leukemia, Multiple myeloma | Failed Discontinued |